Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2011

01-08-2011 | Original Article

Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer

Authors: Takafumi Toita, Shingo Kato, Satoshi Ishikura, Kayoko Tsujino, Takeshi Kodaira, Takashi Uno, Kazuo Hatano, Hideyuki Sakurai, Yuzuru Niibe, Tomoko Kazumoto, Tetsuo Nishimura, Ryo Kitagawa, Miki Fukutani, Masahiko Oguchi, Kenji Umayahara, Yasuyuki Hirashima, Yoichi Aoki, Ken Takizawa, and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group

Published in: International Journal of Clinical Oncology | Issue 4/2011

Login to get access

Abstract

Background

To assess radiotherapy protocol compliance in a multi-institutional phase II study of concurrent chemoradiotherapy for patients with locally advanced cancer of the uterine cervix (JGOG1066).

Methods

For study protocol development, various radiotherapy parameters were examined and consensus was reached by Japanese radiation oncologists with cervical cancer treatment expertise. Quality assurance (QA) was also discussed and included in the protocol. A credentialing process was used to select institutions for participation in the study. Individual case reviews referring to 18 QA items were undertaken for each patient. Radiotherapy data were submitted to the Japanese Gynecologic Oncology Group (JGOG) data center and reviewed by the members of the radiotherapy committee. The QA evaluation was classed as per protocol, deviation, and violation.

Results

Individual case reviews were performed on 69 of 72 patients entered in the study. In 24 patients (35%), there were no deviations for any QA items. There were also no deviations seen for 5 of the 18 items in 69 patients evaluated. Deviations of 64 QA items were seen in 45 cases, and violations were seen in 4 cases (4 items). The most common deviation concerned appropriate application for the external beam radiotherapy (EBRT) boost to involved nodes or parametrium (32 cases). The 4 violations were identified in the QA items regarding high-dose rate intracavitary brachytherapy.

Conclusions

Radiotherapy protocol compliance was favorable except for the EBRT boost indications. The results of this study validate the quality of radiotherapy in JGOG1066, and indicate that the final analysis will provide meaningful results.
Literature
2.
go back to reference Ikushima H, Osaki K, Furutani S et al (2006) Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med 24:115–121PubMedCrossRef Ikushima H, Osaki K, Furutani S et al (2006) Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med 24:115–121PubMedCrossRef
3.
go back to reference Watanabe Y, Nakai H, Shimaoka M et al (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol 11:309–313PubMedCrossRef Watanabe Y, Nakai H, Shimaoka M et al (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol 11:309–313PubMedCrossRef
4.
go back to reference Toita T, Moromizato H, Ogawa K et al (2005) Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96:665–670PubMedCrossRef Toita T, Moromizato H, Ogawa K et al (2005) Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96:665–670PubMedCrossRef
5.
go back to reference Anker CJ, Cachoeira CV, Boucher KM et al (2010) Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy. Int J Radiat Oncol Biol Phys 76:704–712PubMedCrossRef Anker CJ, Cachoeira CV, Boucher KM et al (2010) Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy. Int J Radiat Oncol Biol Phys 76:704–712PubMedCrossRef
6.
go back to reference Nag S, Erickson B, Thomadsen B et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 48:201–211PubMedCrossRef Nag S, Erickson B, Thomadsen B et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 48:201–211PubMedCrossRef
7.
go back to reference Toita T, Kodaira T, Shinoda A et al (2008) Patterns of radiotherapy practice for patients with cervical cancer (1999–2001): patterns of care study in Japan. Int J Radiat Oncol Biol Phys 70:788–794PubMedCrossRef Toita T, Kodaira T, Shinoda A et al (2008) Patterns of radiotherapy practice for patients with cervical cancer (1999–2001): patterns of care study in Japan. Int J Radiat Oncol Biol Phys 70:788–794PubMedCrossRef
8.
go back to reference Toita T, Kato S, Niibe Y et al (2011) Prospective multi-institutional study of definitive radiotherapy with high-dose rate intracavitary brachytherapy in patients with non-bulky (<4 cm) stage I,II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (in press) Toita T, Kato S, Niibe Y et al (2011) Prospective multi-institutional study of definitive radiotherapy with high-dose rate intracavitary brachytherapy in patients with non-bulky (<4 cm) stage I,II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (in press)
9.
go back to reference Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124PubMedCrossRef Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124PubMedCrossRef
10.
go back to reference International Commission on Radiation Units and Measurements (1985) Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU report 38. ICRU, Bethesda, MD International Commission on Radiation Units and Measurements (1985) Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU report 38. ICRU, Bethesda, MD
11.
go back to reference Lowenstein JR, Roll J, Hanson WF et al (2002) Radiotherapy quality assurance of Gynecologic Oncology Group (GOG) protocol 165, a cooperative group study of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54 S1:283 Lowenstein JR, Roll J, Hanson WF et al (2002) Radiotherapy quality assurance of Gynecologic Oncology Group (GOG) protocol 165, a cooperative group study of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54 S1:283
12.
go back to reference Small W Jr, Mell LK, Anderson P et al (2008) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434PubMedCrossRef Small W Jr, Mell LK, Anderson P et al (2008) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434PubMedCrossRef
13.
go back to reference Toita T, Ohno T, Kaneyasu Y et al (2010) A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol 40:456–463PubMedCrossRef Toita T, Ohno T, Kaneyasu Y et al (2010) A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol 40:456–463PubMedCrossRef
14.
go back to reference Lim K, Small W Jr, Portelance L et al (2011) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 79:348–355 Lim K, Small W Jr, Portelance L et al (2011) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 79:348–355
15.
go back to reference Narayan K, van Dyk S, Bernshaw D et al (2009) Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys 74:1529–1535PubMedCrossRef Narayan K, van Dyk S, Bernshaw D et al (2009) Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys 74:1529–1535PubMedCrossRef
16.
go back to reference Petereit DG, Sarkaria JN, Potter DM et al (1999) High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence—the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 45:1267–1274PubMedCrossRef Petereit DG, Sarkaria JN, Potter DM et al (1999) High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence—the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 45:1267–1274PubMedCrossRef
17.
go back to reference Toita T, Oguchi M, Ohno T et al (2009) Quality assurance in the prospective multi-institutional trial on definitive radiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer: the individual case review. Jpn J Clin Oncol 39:813–819PubMedCrossRef Toita T, Oguchi M, Ohno T et al (2009) Quality assurance in the prospective multi-institutional trial on definitive radiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer: the individual case review. Jpn J Clin Oncol 39:813–819PubMedCrossRef
18.
go back to reference Viswanathan AN, Erickson BA (2010) Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 76:104–109PubMedCrossRef Viswanathan AN, Erickson BA (2010) Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 76:104–109PubMedCrossRef
19.
go back to reference Gerbaulet A, Potter R, Haie-Meder C (2002) Cervical carcinoma. In: Gerbaulet A, Potter R, Mazeron J-J et al (eds) The GEC ESTRO handbook of brachytherapy. ESTRO, Brussels, pp 301–363 Gerbaulet A, Potter R, Haie-Meder C (2002) Cervical carcinoma. In: Gerbaulet A, Potter R, Mazeron J-J et al (eds) The GEC ESTRO handbook of brachytherapy. ESTRO, Brussels, pp 301–363
20.
go back to reference Toita T (2009) Current status and perspectives of brachytherapy for cervical cancer. Int J Clin Oncol 14:25–30PubMedCrossRef Toita T (2009) Current status and perspectives of brachytherapy for cervical cancer. Int J Clin Oncol 14:25–30PubMedCrossRef
Metadata
Title
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer
Authors
Takafumi Toita
Shingo Kato
Satoshi Ishikura
Kayoko Tsujino
Takeshi Kodaira
Takashi Uno
Kazuo Hatano
Hideyuki Sakurai
Yuzuru Niibe
Tomoko Kazumoto
Tetsuo Nishimura
Ryo Kitagawa
Miki Fukutani
Masahiko Oguchi
Kenji Umayahara
Yasuyuki Hirashima
Yoichi Aoki
Ken Takizawa
and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group
Publication date
01-08-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0196-4

Other articles of this Issue 4/2011

International Journal of Clinical Oncology 4/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine